Dual Enzyme Cascade-Activated Popcorn-Like Nanoparticles Efficiently Remodeled Stellate Cells to Alleviate Pancreatic Desmoplasia
Source abstract
Abstract
In pancreatic cancer, excessive desmoplastic stroma severely impedes drug access to tumor cells. By reverting activated pancreatic stellate cells (PSCs) to quiescence, all-trans retinoic acid (ATRA) can attenuate their stromal synthesis and remodel the tumor-promoting microenvironment. However, its modulatory effects have been greatly weakened due to its limited delivery to PSCs. Therefore, we constructed a tripeptide RFC-modified gelatin/oleic acid nanoparticle (RNP@ATRA), which delivered ATRA in an enzyme-triggered popcorn-like manner and effectively resolved the delivery challenges. Specifically, surface RFC was cleaved by aminopeptidase N (APN) on the tumor endothelium to liberate l-arginine, generating nitric oxide (NO) for tumor-specific vasodilation. Then, massive nanoparticles were pushed from the vessels into tumors, showing 5.1- and 4.0-fold higher intratumoral accumulation than free ATRA and APN-inert nanoparticles, respectively. Subsequently, in the interstitium, matrix metalloproteinase-2-induced gelatin degradation caused RNP@ATRA to rapidly release ATRA, promoting its interstitial penetration and PSC delivery. Thus, activated PSCs were efficiently reverted to quiescence, and stroma secretion and vascular compression were reduced, thereby enhancing intratumoral delivery of small-molecule or nanosized chemotherapeutics. Ultimately, RNP@ATRA combined with chemotherapeutics markedly suppressed tumor growth and metastasis without causing additional toxicities. Overall, this work provides a potential nanoplatform for the efficient delivery of PSC-modifying agents in pancreatic cancer and other stroma-rich tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic and Hepatic Oncology Research · Nanoparticle-Based Drug Delivery · Phagocytosis and Immune Regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China
School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China
Institute of Translational Medicine, Shanghai University, Shanghai 200444, China
Funding
Natural Science Foundation of Shanghai Municipality · Hubei Provincial Department of Education · National Natural Science Foundation of China
References (44)
Show source-provided references
1. 10.1186/s13046-020-01787-510.1186/s13046-020-01787-5 ↗
2. 10.1038/s41571-019-0281-610.1038/s41571-019-0281-6 ↗
3. 10.1038/nrclinonc.2016.11910.1038/nrclinonc.2016.119 ↗
4. 10.1038/s41575-020-0300-110.1038/s41575-020-0300-1 ↗
5. 10.1016/j.cell.2014.08.00710.1016/j.cell.2014.08.007 ↗
6. 10.1038/s41467-018-05906-x10.1038/s41467-018-05906-x ↗
7. 10.1056/NEJMoa130436910.1056/NEJMoa1304369 ↗
8. 10.1158/1078-0432.CCR-15-201010.1158/1078-0432.CCR-15-2010 ↗
9. 10.1016/j.ccr.2014.04.00510.1016/j.ccr.2014.04.005 ↗
10. 10.1016/j.ccr.2014.04.02110.1016/j.ccr.2014.04.021 ↗
11. 10.1200/JCO.2015.62.871910.1200/JCO.2015.62.8719 ↗
12. 10.1146/annurev-cellbio-100617-06285510.1146/annurev-cellbio-100617-062855 ↗
13. 10.1038/labinvest.2012.16110.1038/labinvest.2012.161 ↗
14. 10.1053/j.gastro.2015.02.04310.1053/j.gastro.2015.02.043 ↗
15. 10.1038/s41467-020-18636-w10.1038/s41467-020-18636-w ↗
16. 10.1002/ajh.2071710.1002/ajh.20717 ↗
17. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
18. 10.1016/j.jconrel.2015.08.01710.1016/j.jconrel.2015.08.017 ↗
19. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
20. 10.1039/C7CS00663B10.1039/C7CS00663B ↗
21. 10.1002/adfm.20210060510.1002/adfm.202100605 ↗
22. 10.1002/advs.20190274610.1002/advs.201902746 ↗
23. 10.1016/j.biomaterials.2020.12062010.1016/j.biomaterials.2020.120620 ↗
24. 10.1111/j.1349-7006.2010.01826.x10.1111/j.1349-7006.2010.01826.x ↗
25. Pasqualini R. · Cancer Res. · 2000 · 60 · 722
26. 10.1007/BF0016448710.1007/BF00164487 ↗
27. 10.1016/j.jphs.2015.09.00210.1016/j.jphs.2015.09.002 ↗
28. 10.1039/c2cs15273h10.1039/c2cs15273h ↗
29. Määttä M. · Clin. Cancer Res. · 2000 · 6 · 2726
30. 10.1021/acsnano.7b0102610.1021/acsnano.7b01026 ↗
31. 10.1021/jacs.5b0092210.1021/jacs.5b00922 ↗
32. 10.1016/j.jconrel.2013.09.01910.1016/j.jconrel.2013.09.019 ↗
33. 10.1016/j.canlet.2005.11.05110.1016/j.canlet.2005.11.051 ↗
34. 10.1039/C9NR09610H10.1039/C9NR09610H ↗
35. 10.1158/0008-5472.CAN-16-086610.1158/0008-5472.CAN-16-0866 ↗
36. 10.1023/A:101252212029410.1023/A:1012522120294 ↗
37. 10.1038/nrc.2017.9210.1038/nrc.2017.92 ↗
38. 10.1021/acsnano.5b0778110.1021/acsnano.5b07781 ↗
39. 10.1016/j.ccell.2014.10.01510.1016/j.ccell.2014.10.015 ↗
40. 10.1016/j.apsb.2015.05.00710.1016/j.apsb.2015.05.007 ↗
41. 10.1053/j.gastro.2018.12.03810.1053/j.gastro.2018.12.038 ↗
42. 10.1016/j.cell.2016.11.03710.1016/j.cell.2016.11.037 ↗
43. 10.1038/s41467-021-23466-510.1038/s41467-021-23466-5 ↗
44. 10.1079/BJN1992009510.1079/BJN19920095 ↗